Leap Therapeutics Inc (STU:5MC)
€ 2.62 -0.1 (-3.68%) Market Cap: 101.82 Mil Enterprise Value: 42.34 Mil PE Ratio: 0 PB Ratio: 2.27 GF Score: 35/100

Leap Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 08:40PM GMT
Release Date Price: €17.9 (+2.29%)
Douglas E. Onsi
Leap Therapeutics, Inc. - CFO, General Counsel, Treasurer & Secretary, President, CEO & Director

Good afternoon. I'm Doug Onsi, the President and CEO of Leap Therapeutics, and it's a pleasure to be able to start a year here in the virtual grand ballroom at the JPMorgan 38th Annual Healthcare Conference. I'm very excited to be able to give you an update on Leap Therapeutics to introduce those of you who are new to Leap or our company, an update on DKN-01, our clinical development program and our plans for a very big year ahead in 2021.

If you turn to Slide 2, you'll see that my presentation will include forward-looking statements.

Moving -- advancing to Slide 3. So Leap Therapeutics is an oncology drug development company that's focused on developing our DKN-01 monoclonal antibody. DKN-01 targets DKK1, which is a protein produced by cancer cells that modulates important immune signaling pathways in tumor cell signaling pathways and plays a key role in maintaining an immunosuppressive tumor microenvironment.

1 year ago, we announced a strategic

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot